Senate Commerce Committee Statement to Assembly, No. 5017 (2R) — State of New Jersey (November 17, 2025)

Summary

A Senate Commerce Committee statement to the Second Reprint of Assembly, No. 5017, State of New Jersey, dated November 17, 2025, reporting the bill favorably with committee amendments. The bill exempts insurance-support organizations and national securities associations from current-law requirements to notify consumers of the collection and disclosure of personal data. As amended, it also exempts information treated like protected health information under HIPAA when handled in accordance with HIPAA, and human subjects research conducted under certain good clinical practice guidelines. The definition of de-identified data is expanded to include data de-identified under HIPAA where recipients are contractually barred from reidentifying it.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SENATE COMMERCE COMMITTEE

STATEMENT TO

[Second Reprint]

ASSEMBLY,
No. 5017

with
committee amendments

STATE
OF NEW JERSEY

DATED: NOVEMBER
17, 2025

The Senate Commerce Committee reports favorably and
with committee amendments Assembly Bill No. 5017 (2R).

This bill exempts insurance-support organizations and
national securities associations from the provisions of current law that
require certain entities to notify consumers of collection and disclosure of
personal data. Under current law, insurance institutions and other entities
are exempt from those requirements.

As amended, the bill exempts certain data from
disclosure requirements under current law, including:

(1) information treated like protected health
information collected, used, or disclosed by a covered entity or business
associate under the "Health Insurance Portability and Accountability Act
of 1996" (HIPAA), when the information is used or disclosed in accordance
with HIPAA and the information is afforded all the privacy protections and
security safeguards of the federal laws and implementing regulations under
HIPAA; and

(2) human subjects research conducted in accordance
with good clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Finally, as amended, the bill expands the definition
of de-identified data under current law to include data de-identified in
accordance with the requirements in HIPAA, where any recipients of that data
are contractually prohibited from attempting to reidentify the data.

As amended and reported by the committee, Assembly
Bill No. 5017 (2R) is identical to Senate Bill No. 4259, which was also amended
and reported by the committee on this date.

COMMITTEE AMENDMENTS :

The committee amended the bill to:

(1) exempt certain data from disclosure requirements
under current law, including:

(a) information treated like protected health
information collected, used, or disclosed by a covered entity or business
associate under HIPAA, when the information is used or disclosed in accordance
with HIPAA and the information is afforded all the privacy protections and
security safeguards of the federal laws and implementing regulations under
HIPAA; and

(b) human subjects research conducted in accordance
with good clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; and

(2) expand the definition of de-identified data under
current law to include data de-identified in accordance with the requirements
in HIPAA, where any recipients of that data are contractually prohibited from
attempting to reidentify the data.

File and source

File

2025-11-17_SCM_A5017_S3.htm

Size

5,593 bytes

SHA-256

4fef985192839c268426e1e3546b2fc8e5ab475f15a375183139f98ab43bd318

Our copy

2025-11-17_SCM_A5017_S3.htm

Original

No public link identified.